NPIL in drug discovery agreement with Merck
Nicholas Piramal India Limited (NPIL) and Merck & Co Inc, which operates in India through its subsidiary, MSD Pharmaceuticals Private Ltd, have agreed a research and development collaboration to discover and develop new drugs for two selected targets provided by Merck.
Nicholas Piramal India Limited (NPIL) and Merck & Co Inc, which operates in India through its subsidiary, MSD Pharmaceuticals Private Ltd, have agreed a research and development collaboration to discover and develop new drugs for two selected targets provided by Merck.
NPIL will be responsible for carrying out an integrated drug discovery programme from hits to leads through pre-clinical candidate selection, followed by Investigational New Drug (IND)-enabling non-clinical studies and human clinical trials demonstrating proof-of-concept primarily for Oncology.
Merck will have an option to advance the most promising drug candidates into late stage clinical trials and to commercialise these drug candidates.
NPIL will be eligible to receive milestone payments associated with progress in the development of drug candidates of up to $175 million per target, plus royalties on sales of any products resulting from the collaboration.
